We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
Cap. Flow
+$308M
Cap. Flow %
18.12%
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$40.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$36.2M
4
INSP icon
Inspire Medical Systems
INSP
+$27.3M
5
VIR icon
Vir Biotechnology
VIR
+$21.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$39.4M
2
RAPT
RAPT Therapeutics
RAPT
+$17.3M
3
CDTX
Cidara Therapeutics
CDTX
+$13.2M
4
FULC icon
Fulcrum Therapeutics
FULC
+$10.4M
5
ABUS icon
Arbutus Biopharma
ABUS
+$9.98M

Sector Composition

Rank Sector Weight
1 Healthcare 88.42%
2 Miscellaneous 9.68%
3 Financials 1.51%
4 Technology 0.08%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALA icon
301
KALA BIO
KALA
$13.3M
$24.5K ﹤0.01%
2,830
– –
CHRS icon
302
Coherus Oncology
CHRS
$218M
$17.5K ﹤0.01%
10,366
– –
PRQR icon
303
ProQR Therapeutics
PRQR
$323M
$16.2K ﹤0.01%
10,000
– –
QNCX icon
304
Quince Therapeutics
QNCX
$34.3M
$5.08K ﹤0.01%
251
+36
+17% +$7.23K
QNCX icon
305
PUT
Quince Therapeutics
QNCX
$34.3M
$5.07K ﹤0.01%
250
-150
-38% -$30.1K
AQST icon
306
PUT
Aquestive Therapeutics
AQST
$630M
– –
-254,000
Closed -$1.64M
ATXS
307
DELISTED
Astria Therapeutics
ATXS
– –
-173,557
Closed -$2.27M
AUPH icon
308
Aurinia Pharmaceuticals
AUPH
$2.17B
– –
-22,000
Closed -$351K
AVDL
309
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-150,532
Closed -$3.24M
AZN icon
310
AstraZeneca
AZN
$252B
– –
-4,500
Closed -$827K
CDTX
311
DELISTED
Cidara Therapeutics
CDTX
– –
-59,677
Closed -$13.2M
CTMX icon
312
CALL
CytomX Therapeutics
CTMX
$699M
– –
-100,000
Closed -$426K
DVAX
313
DELISTED
Dynavax Technologies
DVAX
– –
-170,000
Closed -$2.61M
DYN icon
314
CALL
Dyne Therapeutics
DYN
$4.68B
– –
-10,000
Closed -$196K
FULC icon
315
CALL
Fulcrum Therapeutics
FULC
$294M
– –
-65,000
Closed -$735K
GBIO
316
DELISTED
Generation Bio
GBIO
– –
-22,144
Closed -$126K
GOSS icon
317
CALL
Gossamer Bio
GOSS
$83.2M
– –
-35,100
Closed -$109K
GOSS icon
318
PUT
Gossamer Bio
GOSS
$83.2M
– –
-463,200
Closed -$1.44M
IDXX icon
319
Idexx Laboratories
IDXX
$43.7B
– –
-400
Closed -$271K
IMUX icon
320
Immunic
IMUX
$210M
$0 ﹤0.01%
+3,000
New +$26.9K
INO icon
321
CALL
Inovio Pharmaceuticals
INO
$133M
– –
-75,500
Closed -$131K
IOBT
322
DELISTED
IO Biotech
IOBT
– –
-24,964
Closed -$15.2K
IWM icon
323
iShares Russell 2000 ETF
IWM
$80.8B
– –
-12,070
Closed -$3.11M
NGNE icon
324
Neurogene
NGNE
$732M
– –
-30,633
Closed -$631K
NVCR icon
325
NovoCure
NVCR
$2.08B
– –
-34,000
Closed -$440K
10 11 12
13
14

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
  • ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
  • ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
  • ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
  • ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
  • ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
  • ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.